AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor blocks the ERK1/2 signaling pathway, inhibits osteoclast differentiation and activation in multiple myeloma: Clinical implications.

被引：2
|
作者：
Breitkreutz, Iris [1 ]
Vallet, Sonia [1 ]
Raab, Marc S. [1 ]
Li, Xianfeng [1 ]
Raje, Noopur [1 ]
Hideshima, Teru [1 ]
Chauhan, Dharminder [1 ]
Munshi, Nikhil [1 ]
Anderson, Kenneth C. [1 ]
Tai, Yu-Tzu [1 ]
机构：
[1] Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3467.3467
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3467
引用
收藏
页码：989A / 989A
页数：1
相关论文
共 50 条
  • [1] Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244).
    Doyle, MP
    Yeh, TC
    Suzy, B
    Morrow, M
    Lee, PA
    Hughes, AM
    Cartlidge, S
    Wallace, E
    Lyssikatos, J
    Eckhardt, SG
    Winkler, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 210S - 210S
  • [2] AZD6244, a MEK1/2 inhibitor, inhibits osteoclast differentiation and activity in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Chauhan, D.
    Munshi, N.
    Richardson, P.
    Tai, Y. T.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 131 - 131
  • [3] A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata
    Zingone, Adriana
    Kmieciak, Maciej
    Bose, Prithviraj
    Badros, Ashraf Z.
    Voorhees, Peter M.
    Baz, Rachid
    Korde, Neha
    Lin, Hui-Yi
    Chen, Jin-Qiu
    Herrmann, Michelle
    Xi, Liqiang
    Raffeld, Mark
    Zhao, Xiuhua
    Wan, Wen
    Tombes, Mary Beth
    Shrader, Ellen
    Weir-Wiggins, Caryn
    Sankala, Heidi
    Hogan, Kevin T.
    Doyle, Austin
    Annunziata, Christina M.
    Wellons, Martha
    Roberts, John D.
    Sullivan, Daniel
    Landgren, Ola
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1067 - 1075
  • [4] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Balagula, Yevgeniy
    Huston, Katherine Barth
    Busam, Klaus J.
    Lacouture, Mario E.
    Chapman, Paul B.
    Myskowski, Patricia L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1114 - 1121
  • [5] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Yevgeniy Balagula
    Katherine Barth Huston
    Klaus J. Busam
    Mario E. Lacouture
    Paul B. Chapman
    Patricia L. Myskowski
    Investigational New Drugs, 2011, 29 : 1114 - 1121
  • [6] Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.
    Tai, Yu-Tzu
    Li, Xian-Feng
    Breitkreutz, Iris
    Song, Weihua
    Burger, Peter
    Rumizen, Matthew
    Hideshima, Teru
    Podar, Klaus
    Ghobrial, Irene
    Schlossman, Robert
    Richardson, Paul
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 987A - 987A
  • [7] Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours
    Desar, Ingrid M. E.
    Bovenschen, H. Jorn
    Timmer-Bonte, Anja J. N. H.
    Cantarini, Mireille V.
    van der Graaf, Winette T. A.
    van Rossum, Michelle M.
    van Herpen, Carla M. L.
    ACTA ONCOLOGICA, 2010, 49 (01) : 113 - 116
  • [8] The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo
    Haass, N. K.
    Smalley, K. S.
    Sproesser, K.
    Contractor, R.
    Herlyn, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S156 - S156
  • [9] AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor, enhances tamoxifen sensitivity in resistant ER-positive/HER2-positive breast cancer cells with constitutively elevated MEK1/2
    Zhou, Yamei
    Benz, Chrisptopher C.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Yeh, Tammie C.
    Marsh, Vivienne
    Bernat, Bryan A.
    Ballard, Josh
    Colwell, Heidi
    Evans, Ron J.
    Parry, Janet
    Smith, Darin
    Brandhuber, Barbara J.
    Gross, Stefan
    Marlow, Allison
    Hurley, Brian
    Lyssikatos, Joe
    Lee, Patrice A.
    Winkler, James D.
    Koch, Kevin
    Wallace, Eli
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1576 - 1583
12345